2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

Benjamin Besse, Alex Adjei, Paul Baas, Peter Meldgaard, M. Nicolson, Luis Paz-Ares, Martin Reck, Egbert F. Smit, Konstantinos Syrigos, R. Stahel, E. Felip, S. Peters, Rolf Stahel, Enriqueta Felip, Solange Peters, Keith Kerr, Benjamin Besse, Johan Vansteenkiste, Wilfried Eberhardt, Martin EdelmanTony Mok, Ken O'Byrne, Silvia Novello, Lukas Bubendorf, Antonio Marchetti, Paul Baas, Martin Reck, Konstantinos Syrigos, Luis Paz-Ares, Egbert F. Smit, Peter Meldgaard, Alex Adjei, Marianne Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre-Finn, Gaetano Rocco, Giulia Veronesi, Jean Yves Douillard, Eric Lim, Christophe Dooms, Walter Weder, Dirk De Ruysscher, Cecile Le Pechoux, Paul De Leyn, Virginie Westeel

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.

Original languageEnglish
Article numbermdu123
Pages (from-to)1475-1484
Number of pages10
JournalAnnals of Oncology
Volume25
Issue number8
Early online date25 Mar 2014
DOIs
Publication statusPublished - 1 Aug 2014

Keywords

  • Consensus
  • Esmo
  • Further lines
  • Non-small-cell lung cancer

Fingerprint Dive into the research topics of '2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease'. Together they form a unique fingerprint.

Cite this